Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)

[1]  R. Warrington,et al.  Primary immunodeficiency , 2011, Allergy, Asthma & Clinical Immunology.

[2]  E. Haddad,et al.  20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  J. Lawo,et al.  Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency , 2016, Journal of Clinical Immunology.

[4]  A N N Gardulf,et al.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease , 2015, Clinical and experimental immunology.

[5]  C. Cunningham-Rundles,et al.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. , 2014, Immunotherapy.

[6]  J. Edelman,et al.  Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency , 2014, Biologics in therapy.

[7]  E. Haddad,et al.  SCIg vs IVIg: Let’s Give Patients the Choice! , 2014, Journal of Clinical Immunology.

[8]  J. Casanova,et al.  Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015 , 2015, Journal of Clinical Immunology.

[9]  C. Landersdorfer,et al.  Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency , 2013, Postgraduate medicine.

[10]  A. Fasth,et al.  Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review , 2013, Drugs.

[11]  J. Orange,et al.  Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy , 2012, Clinical and experimental immunology.

[12]  A N N Gardulf.  Immunoglobulin Treatment for Primary Antibody Deficiencies , 2012, BioDrugs.

[13]  J. Casanova,et al.  Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought , 2012, Journal of Clinical Immunology.

[14]  R. Shapiro.  Why I Use Subcutaneous Immunoglobulin (SCIG) , 2012, Journal of Clinical Immunology.

[15]  V. Wahn,et al.  Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. , 2011, Clinical immunology.

[16]  J. Orange,et al.  Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation , 2011, Immunologic research.

[17]  Steven M. Holland,et al.  Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015 , 2009, Front. Immun..

[18]  S. Spector,et al.  Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency , 2010, Journal of Clinical Immunology.

[19]  R. Shapiro.  Subcutaneous Immunoglobulin Therapy by Rapid Push is Preferred to Infusion by Pump: A Retrospective Analysis , 2010, Journal of Clinical Immunology.

[20]  L. Notarangelo,et al.  Immunodeficiencies , 2009, Clinical and experimental immunology.

[21]  V. Bonagura,et al.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. , 2008, The Journal of allergy and clinical immunology.

[22]  L. Hammarström,et al.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies , 2008, Clinical and experimental immunology.

[23]  D. Hamrock,et al.  Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.

[24]  M. Berger.  Subcutaneous immunoglobulin replacement in primary immunodeficiencies. , 2004, Clinical immunology.

[25]  R. Buckley.  Primary cellular immunodeficiencies. , 2002, The Journal of allergy and clinical immunology.

[26]  S. Misbah,et al.  Adverse Effects of Intravenous Immunoglobulin , 1993, Drug safety.

[27]  R. Buckley,et al.  The use of intravenous immune globulin in immunodeficiency diseases. , 1991, The New England journal of medicine.

[28]  IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice. , 1983, Clinical and experimental immunology.

[29]  H. Ochs,et al.  Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. , 1982, Clinical immunology and immunopathology.